Administration of anti-IgE to a Churg-Strauss syndrome patient

International Archives of Allergy and Immunology

Volumn 144, Issue 2, 2007, Pages 155-158

  Giavina Bianchi, Pedro ^a,b   Giavina Bianchi, Mara ^a   Agondi, Rosana ^a   Kalil, Jorge ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Jd América ^*  (Brazil)

Author keywords

Anti IgE; Asthma; Churg Strauss syndrome; Eosinophilia; IgE; Severe asthma; Vasculitis

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CICLESONIDE; CORTICOSTEROID; FORMOTEROL; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; STEROID;

ADULT; ARTICLE; ASTHMA; BLOOD CELL COUNT; CASE REPORT; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG MEGADOSE; EOSINOPHILIA; HUMAN; LUNG FUNCTION; MALE; MORBIDITY; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; CHURG-STRAUSS SYNDROME; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34548662419     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103228     Document Type: Article

References (20)

1. Masi AT, Hunder GG, Lie JT, et al: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-1100.
2. Jennette JC, Falk RJ, Andrassy K, et al: Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192.
3. Lanham JG, Elkon KB, Pusey CD, Hughes GR: Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984;63:65-81.
4. Churg J, Strauss L: Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol 1951;27:277-294.
5. Keogh K, Specks U: Churg-Strauss syndrome. Semin Respir Crit Care Med 2006;27:148-157.
6. Oh MJ, Lee JY, Kwon NH, Choi DC: Churg-Strauss syndrome: the clinical features and long-term follow-up of 17 patients. J Korean Med Sci 2006;21:265-271.
7. Guillevin L, Pagnoux C, Mouthon L: Churg-Strauss syndrome. Semin Respir Crit Care Med 2004;25:535-545.
8. Guillevin L, Lhote F, Gayraud M, et al: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17-28.
9. Lanham JG: Churg-Strauss syndrome. Br J Hosp Med 1992;47:667-673.
10. Watts RA, Carruthers DM, Scott DG: Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995;25:28-24.
11. Danieli MG, Cappelli M, Malcangi G, et al: Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004;63:1649-1654.
12. Tsurikisawa N, Taniguchi M, Hiroshi S, et al: Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004;92:80-87.
13. Jayne DR, Chapel H, Adu D, et al: Intravenous immunoglobulin for anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with persistent disease activity. Q J Med 2000;93:433-439.
14. Humbert M, Beasley R, Ayres J, et al: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-316.
15. Fahy JV, Fleming HE, Wong HH, et al: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-1834.
16. Winchester DE, Jacob A, Murphy T: Omalizumab for asthma (correspondence). N Engl J Med 2006;355:1281-1282.
17. Noga O, Hanf G, Kunkel G: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131:46-52.
18. Djukanovic R, Wilson SJ, Kraft M, et al: Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Resp Crit Care Med 2004;170:583-593.
19. Noga O, Hanf G, Brachmann I, et al: Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117:1493-1499.
20. US Food and Drug Administration: Briefing document on safety. Omalizumab (Xolair) (recombinant humanized monoclonal antibody to IgE) for treatment of allergic asthma. http://www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf.